CRISPR Therapeutics AG

23 ott 2026, 21:11 UTC

CRISPR Therapeutics AG shares rose in after-market trading, reflecting broader market gains amid strong business activity growth and improved consumer sentiment.

22 ott 2026, 23:56 UTC

CRISPR Therapeutics AG is trading slightly higher in after-market hours, reflecting a modest increase since Thursday's close while remaining below its 20-day moving average.

21 ott 2026, 23:01 UTC

CRISPR Therapeutics AG shares are trading modestly lower in after-market hours, reflecting unusual volatility and remaining significantly below their 20-day moving average.

20 ott 2026, 23:06 UTC

CRISPR Therapeutics AG is trading modestly higher in after-market hours, recovering from earlier fluctuations but remains below its 20-day moving average.

19 ott 2026, 23:01 UTC

CRISPR Therapeutics AG CFO Raju Prasad steps down, with A.J. Silver appointed as his successor, as the company continues to face after-market pressure.

16 ott 2026, 23:06 UTC

CRISPR Therapeutics AG is down in after-market trading, having retraced from earlier gains and currently sitting just below Friday's close.

15 ott 2026, 23:26 UTC

UBS initiated coverage on CRISPR Therapeutics AG with a Neutral rating and set a price target of $52, announced after the market closed.

14 ott 2026, 23:45 UTC

UBS initiated coverage on CRISPR Therapeutics AG with a Neutral rating and set a price target of $52.00, contributing to a modest after-market decline.

13 ott 2026, 20:07 UTC

CRISPR Therapeutics AG shares are declining amid a broader biotechnology sector downturn, with the SPDR S&P Biotech ETF (XBI) also lower due to key holdings' drops.

12 ott 2026, 22:51 UTC

CRISPR Therapeutics AG shares advanced modestly in after-market trading, despite a notable decline from an earlier high following Monday's close.

9 ott 2026, 23:25 UTC

CRISPR Therapeutics AG's shares showed little change during after-market hours, trading within a narrow range and remaining below their 20-day moving average.

8 ott 2026, 23:05 UTC

CRISPR Therapeutics AG will present Phase 1b trial data for CTX310® at the American Heart Association Scientific Sessions 2026, scheduled for November 6-9, 2026.

7 ott 2026, 23:00 UTC

CRISPR Therapeutics AG is higher in after-market trading, recovering from three lower sessions, with cumulative returns peaking at 1.11% before retracing slightly to 1.05%.

6 ott 2026, 20:00 UTC

The ARK Genomic Revolution ETF fell sharply as key holdings Guardant Health and Absci Corp. declined following disappointing study results.

5 ott 2026, 23:15 UTC

CRISPR Therapeutics AG is trading modestly higher in after-market hours, positioned above its 20-day moving average and near the upper end of its one-month trading range.

2 ott 2026, 20:07 UTC

CRISPR Therapeutics AG shares fell sharply, pulling back from earlier gains amid a broader market trend of slight declines since Thursday's close.

1 ott 2026, 20:07 UTC

CRISPR Therapeutics AG advanced during Thursday's trading session, reflecting a modest gain since Wednesday's close, despite earlier pulling back from a session high.

30 set 2026, 23:01 UTC

CRISPR Therapeutics AG is trading modestly higher in after-market hours following a pullback from an earlier peak during the regular session.

29 set 2026, 23:06 UTC

CRISPR Therapeutics AG's shares were roughly flat during after-market hours, trading within a narrow range and above the 20-day moving average.

28 set 2026, 22:31 UTC

CRISPR Therapeutics AG advanced during after-market hours, continuing its upward movement despite a recent trend of lower trading in the broader biotechnology sector.

25 set 2026, 23:00 UTC

CRISPR Therapeutics AG sees a modest increase in after-market trading following Friday's close, positioned around the midpoint of its one-month trading range.

24 set 2026, 23:00 UTC

CRISPR Therapeutics AG is trading lower in after-market hours, reaching its lowest point since Thursday amid rising Treasury yields and geopolitical tensions.

23 set 2026, 20:02 UTC

Shares of CRISPR Therapeutics AG are declining sharply following Anthropic's announcement of a novel enzyme system with similarities to CRISPR, raising competitive concerns.

22 set 2026, 23:31 UTC

CRISPR Therapeutics AG is rising in after-market trading, gaining ground since Tuesday's close and remaining above its 20-day moving average.

21 set 2026, 23:51 UTC

CRISPR Therapeutics AG is trading modestly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

19 set 2026, 00:02 UTC

CRISPR Therapeutics AG is advancing in after-market trading, likely in sympathy with Editas Medicine Inc, amid broader economic concerns.

18 set 2026, 23:01 UTC

CRISPR Therapeutics AG is advancing in after-market trading, moving higher alongside the broader market, following a peak return earlier in the session.

17 set 2026, 23:51 UTC

CRISPR Therapeutics AG declined modestly during after-market hours on Thursday, breaking a recent trend of higher daily closes.

16 set 2026, 23:16 UTC

CRISPR Therapeutics AG is declining in after-market hours, trading near the lower end of its one-month range and below its 20-day moving average.

15 set 2026, 23:01 UTC

CRISPR Therapeutics AG shares are higher in after-market hours, reflecting overall market momentum despite a decline in the New York Empire State Manufacturing Index.